Page last updated: 2024-12-08

gw 257406x

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

maribavir: has antiviral activity against human cytomegalovirus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID471161
CHEMBL ID515408
SCHEMBL ID791309
MeSH IDM0466831

Synonyms (59)

Synonym
camvia
gw-1263
gw-257406x
vp-41263
bw-1263w94
maribavir (usan/inn)
D04859
camvia (tn)
5,6-dichloro-2-(isopropylamino)-1-(.beta.-l-ribofuranosyl)benzimidazole
camvia(tm)
(2s,3s,4r,5s)-2-[5,6-dichloro-2-(isopropylamino)benzimidazol-1-yl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
maribavir
benzimidavir
1263w94
176161-24-3
G1263 ,
(2s,3s,4r,5s)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol
1263-w-94
livtencity
CHEMBL515408
(2s,3s,4r,5s)-2-(5,6-dichloro-2-(isopropylamino)-1h-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
AKOS015962194
5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosyl-1h-benzimidazole
gw257406x
bw 1263w94
gw 257406x
5,6-dichloro-n-(1-methylethyl)-1-beta-l-ribofuranosyl-1h-benzimidazol-2-amine
maribavir [usan:inn:ban]
unii-ptb4x93he1
ptb4x93he1 ,
1h-benzimidazol-2-amine, 5,6-dichloro-n-(1-methylethyl)-1-beta-l-ribofuranosyl-
5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosylbenzimidazole
gw 1263
5,6-dichloro-2-(isopropylamino)-1-.beta.-l-ribofuranosylbenzimidazole
maribavir [usan]
maribavir [who-dd]
5,6-dichloro-n-(1-methylethyl)-1-.beta.-l-ribofuranosyl-1h-benzimidazol-2-amine
1h-benzimidazol-2-amine, 5,6-dichloro-n-(1-methylethyl)-1-.beta.-l-ribofuranosyl-
maribavir [inn]
HY-16305
KJFBVJALEQWJBS-XUXIUFHCSA-N
5,6-dichloro-2-(isopropylamino)-1-(beta-l-ribofuranosyl)-1h-benzimidazole
SCHEMBL791309
AC-22286
maribavir (1263w94, benzimidazole d-ribose derivative)
DTXSID60170091 ,
bw1263w94
5,6-dichloro-2-isopropylamino-1-(beta-l-ribofuranosyl)-1h-benzimidazole
DB06234
AS-49903
Q6762512
O10059
NCGC00378559-03
(2s,3s,4r,5s)-2-(5,6-dichloro-2-(isopropylamino)-1h-benzo[d]-imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
gtpl12049
maribavirum
j05ax10
dtxcid0092582
EX-A7816

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" 1263W94 was generally well tolerated; taste disturbance was the most frequently reported adverse event over the 28-day dosing period."( Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding.
Aberg, JA; Drew, WL; Jacobson, MA; Lalezari, JP; Miner, R; Shaw, S; Snowden, W; Talarico, CL; Wang, LH; Wire, MB, 2002
)
0.31
" No severe safety concerns were observed in the evaluation of adverse events, vital signs, electrocardiograms, and clinical laboratory tests following administration of a single dose of 1263W94."( Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects.
Allanson, J; Peck, RW; Wang, LH; Wiggs, R; Wire, MB; Yin, Y, 2003
)
0.32
" Maribavir was well-tolerated and associated with fewer hematological adverse events than oral ganciclovir."( Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial.
Abouljoud, M; Avery, R; Blumberg, E; Chen, H; Clough, L; Ericzon, BG; Garcia-Diaz, JB; Goss, JA; Limaye, AP; Navasa, M; Saliba, F; Troisi, RI; Uknis, ME; Villano, SA; Winston, DJ, 2012
)
0.38
" In terms of safety, letermovir was at least similar in comparison with placebo and most agents while both letermovir and acyclovir showed significantly reduced risk for serious adverse events compared with ganciclovir, with RRs of ."( Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Gagelmann, N; Kröger, N; Ljungman, P; Styczynski, J, 2018
)
0.48
" Seven participants reported treatment-emergent adverse events (TEAEs; Japanese participants, 400 mg: 2 [16."( Pharmacokinetics and Safety Evaluation of Maribavir in Healthy Japanese and Matched White Participants: A Phase 1, Open-Label Study.
Ilic, K; Song, I; Suttle, B; Wu, J, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" 1263W94 was rapidly eliminated, with a mean half-life in plasma of 3 to 5 h; the half-life was independent of the dose level."( Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects.
Allanson, J; Peck, RW; Wang, LH; Wiggs, R; Wire, MB; Yin, Y, 2003
)
0.32
" Blood samples were collected for each drug sequence, and pharmacokinetic parameters for maribavir and its principal metabolite, VP 44469, were determined."( Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
Dougherty, C; Goldwater, DR; Schumacher, M; Villano, SA, 2008
)
0.35
" This was a randomized, double-blind, placebo-controlled study designed to evaluate the potential pharmacokinetic interaction of concomitant administration of maribavir and tacrolimus."( A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients.
Bloom, R; Gelone, S; Johnson, J; Pescovitz, MD; Pirsch, J; Villano, SA, 2009
)
0.35
" With no pediatric clinical data available and difficulty in trial recruitment, population pharmacokinetic modeling and simulations were conducted to predict the pharmacokinetics and inform maribavir dosing in adolescents."( Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus.
Farrell, C; Hayes, S; Song, IH; Sun, K, 2023
)
0.91
" Serial blood samples were collected up to 24 hours after dosing for pharmacokinetic assessments."( Pharmacokinetics and Safety Evaluation of Maribavir in Healthy Japanese and Matched White Participants: A Phase 1, Open-Label Study.
Ilic, K; Song, I; Suttle, B; Wu, J, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)
0.35
" To assess its activity in combination with approved and experimental CMV antivirals, and with the mTor inhibitor rapamycin (sirolimus), drug effects were tested by in vitro checkerboard assays and the data were analyzed using a three dimensional model based on an independent effects definition of additive interactions."( Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus.
Chou, S; Derakhchan, K; Ercolani, RJ, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" However, the oral bioavailability of 3a was only half of that observed for 1263W94."( Synthesis and evaluation of a series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94).
Biron, KK; Chamberlain, SD; Chan, JH; Dark, EH; Davis, MG; Dornsife, RE; Drach, JC; Frick, LW; Harvey, RJ; Koszalka, GW; Selleseth, DW; Townsend, LB,
)
0.13
" Mean oral bioavailability of 1263W94 was >90% in rats and approximately 50% in monkeys."( Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication.
Biron, KK; Boyd, L; Chamberlain, SC; Drach, JC; Good, SS; Johnson, NW; Koszalka, GW; Townsend, LB, 2002
)
0.31
" Its bioavailability is greater than that of oral ganciclovir, but less than that of valganciclovir."( Maribavir: a novel antiviral agent with activity against cytomegalovirus.
Bloom, RD; Blumberg, E; Pote, L; Trofe, J; Wade, E, 2008
)
0.35
"Maribavir is an orally bioavailable benzimidazole riboside in clinical development for treatment of cytomegalovirus infection in patients who undergo transplantation."( Evaluation of the Effect of Maribavir on Cardiac Repolarization in Healthy Participants: Thorough QT/QTc Study.
Ilic, K; Martin, P; Song, I; Wu, J, 2020
)
0.56
"Maribavir, an orally bioavailable antiviral, has shown superior activity against posttransplant cytomegalovirus infection compared with conventional antivirals."( Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open-Label, Single-Dose, Parallel Group Study.
Chen, G; Ilic, K; Song, I; Wu, J, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" Ongoing and planned clinical trials that will study the safety and tolerability of repeated dosing and evaluate the in vivo antiviral activity and ocular penetration of 1263W94, will help to determine the potential of this drug as an improved therapy for CMV disease."( Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease.
Biron, K; Chamberlain, S; Chulay, J; Davis, M; Drach, J; Frick, L; Good, S; Harvey, R; Koszalka, G; Townsend, L; Underwood, M; Wang, L, 1999
)
0.3
" Subjects received one of six dosage regimens (100, 200, or 400 mg three times a day, or 600, 900, or 1,200 mg twice a day) or a placebo for 28 days."( Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding.
Aberg, JA; Drew, WL; Jacobson, MA; Lalezari, JP; Miner, R; Shaw, S; Snowden, W; Talarico, CL; Wang, LH; Wire, MB, 2002
)
0.31
" Dosage ranging studies might benefit future MBV use."( Maribavir use in practice for cytomegalovirus infection in French transplantation centers.
Alain, S; Avettant-Fenoël, V; Coaquette, A; Essig, M; Garrigue, I; Hantz, S; Huynh, A; Kamar, N; Kaminski, H; Lecuit, M; Leruez-Ville, M; Lortholary, O; Mazeron, MC; Mengelle, C; Ploy, MC; Presne, C; Rawlinson, W; Rerolles, JP; Revest, M; Segard, C; Veyer, D, 2013
)
0.39
" With no pediatric clinical data available and difficulty in trial recruitment, population pharmacokinetic modeling and simulations were conducted to predict the pharmacokinetics and inform maribavir dosing in adolescents."( Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus.
Farrell, C; Hayes, S; Song, IH; Sun, K, 2023
)
0.91
" Serial blood samples were collected up to 24 hours after dosing for pharmacokinetic assessments."( Pharmacokinetics and Safety Evaluation of Maribavir in Healthy Japanese and Matched White Participants: A Phase 1, Open-Label Study.
Ilic, K; Song, I; Suttle, B; Wu, J, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (80)

Assay IDTitleYearJournalArticle
AID520252AUC (0 to infinity) in human at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520257Cmax in human plasma at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520251AUC (0 to t) in human at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544646Antiviral activity against Human cytomegalovirus clinical T2294 harboring UL97 T409 mutant gene with UL27 E22stop mutant gene by SEAP yield reduction assay relative to wild type2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520281Toxicity in human assessed as dysgeusia at at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544642Antiviral activity against 0.01 to 0.02 MOI of Human cytomegalovirus T2898 expressing UL27 kinase with W362stop gene N289D, D298G, N300G, P307L, V310A, D351N, I367V mutant gene assessed as growth inhibition at day 6 by SEAP yield reduction assay relative 2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID1450213Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID520267AUC (0 to infinity) in human assessed as VP 44469 at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544449Antiviral activity against Human cytomegalovirus T2867 expressing UL27 kinase with A269T mutant gene by SEAP yield reduction assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520278Apparent oral clearance in human assessed as VP 44469 at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520272Tmax in human plasma assessed as VP 44469 at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544457Ratio of EC50 for Human cytomegalovirus T2890 expressing UL97 kinase with V353A mutant gene to EC50 for Human cytomegalovirus T2211 expressing wild type UL27 gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID544445Antiviral activity against Human cytomegalovirus T2899 expressing wild type UL27 kinase with N289D, D298G, N300G, P307L,V310A, D351N, I367V mutant gene by SEAP yield reduction assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520273Cmax in human plasma assessed as VP 44469 at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544638Ratio of EC50 for Human cytomegalovirus T2931 expressing UL27 kinase 301 to 311 deletion with frame shift mutation at 311 codon to EC50 for Human cytomegalovirus T2211 expressing wild type UL27 gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID544641Antiviral activity against 0.01 to 0.02 MOI of Human cytomegalovirus T2931 expressing UL27 kinase 301 to 311 deletion with frame shift mutation at 311 codon assessed as growth inhibition at day 6 by SEAP yield reduction assay relative to control2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520282Toxicity in human assessed as adverse event at at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520269Apparent oral clearance in human assessed as VP 44469 at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544644Antiviral activity against Human cytomegalovirus clinical isolate C076 harboring UL97 V353A mutant gene with UL27 del 301 to 311 codon by SEAP yield reduction assay relative to wild type2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID544460Ratio of EC50 for Human cytomegalovirus T2867 expressing UL27 kinase with A269T mutant gene to EC50 for Human cytomegalovirus T2211 expressing wild type UL27 gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520284Toxicity in human assessed as headache at at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544456Ratio of EC50 for Human cytomegalovirus T2899 expressing wild type UL27 kinase with N289D, D298G, N300G, P307L,V310A, D351N, I367V mutant gene to EC50 for Human cytomegalovirus T2211 expressing wild type UL27 gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID544452Antiviral activity against Human cytomegalovirus T3020 expressing UL27 kinase with E22stop gene by SEAP yield reduction assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID544459Ratio of EC50 for Human cytomegalovirus T2767 expressing UL27 kinase with L193Fmutant gene to EC50 for Human cytomegalovirus T2211 expressing wild type UL27 gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520265Terminal elimination half-life in human assessed as VP 44469 at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520247Terminal elimination half-life in human at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520264Cmax in human plasma assessed as VP 44469 at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520248Tmax in human plasma at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID1450212Cytotoxicity against African green monkey Vero E6 cells measured after 3 days by trypan blue assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID544454Antiviral activity against Human cytomegalovirus T3019 expressing UL27 kinase with 218delC mutant gene by SEAP yield reduction assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID544455Antiviral activity against Human cytomegalovirus T2931 expressing UL27 kinase 301 to 311 deletion with frame shift mutation at 311 codon by SEAP yield reduction assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520263Tmax in human plasma assessed as VP 44469 at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520259Volume of distribution with respect to oral bioavailability in human at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544451Antiviral activity against Human cytomegalovirus T3037 expressing UL27 kinase with L426F mutant gene by SEAP yield reduction assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID544462Ratio of EC50 for Human cytomegalovirus T3037 expressing UL27 kinase with L426F mutant gene to EC50 for Human cytomegalovirus T2211 expressing wild type UL27 gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520254Apparent oral clearance in human at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544450Antiviral activity against Human cytomegalovirus T3053 expressing UL27 kinase with V353E mutant gene by SEAP yield reduction assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520285Toxicity in human assessed as adverse event at at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520260Apparent oral clearance in human at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520253Volume of distribution with respect to oral bioavailability in human at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544448Antiviral activity against Human cytomegalovirus T2767 expressing UL27 kinase with L193Fmutant gene by SEAP yield reduction assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID544639Antiviral activity against 0.01 to 0.02 MOI of Human cytomegalovirus T2899 expressing wild type UL97 kinase with N289D, D298G, N300G, P307L,V310A, D351N, I367V mutant gene assessed as growth inhibition at day 6 by SEAP yield reduction assay relative to co2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520246AUC (0 to infinity) in human at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520268Volume of distribution with respect to oral bioavailability in human assessed as VP 44469 at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544453Antiviral activity against Human cytomegalovirus T2898 expressing UL27 kinase with W362stop gene N289D, D298G, N300G, P307L, V310A, D351N, I367V mutant gene by SEAP yield reduction assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID544464Ratio of EC50 for Human cytomegalovirus T2898 expressing UL27 kinase with W362stop gene N289D, D298G, N300G, P307L, V310A, D351N, I367V mutant gene to EC50 for Human cytomegalovirus T2211 expressing wild type UL27 gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520266AUC (0 to t) in human assessed as VP 44469 at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544640Antiviral activity against 0.01 to 0.02 MOI of Human cytomegalovirus T2867 expressing UL27 kinase with A269T mutant gene assessed as growth inhibition at day 6 by SEAP yield reduction assay relative to control2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID392516Antiviral activity against Human herpesvirus 6A2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID544461Ratio of EC50 for Human cytomegalovirus T3053 expressing UL27 kinase with V353E mutant gene to EC50 for Human cytomegalovirus T2211 expressing wild type UL27 gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520271Renal clearance in human assessed as VP 44469 at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520276AUC (0 to infinity) in human assessed as VP 44469 at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520280Renal clearance in human assessed as VP 44469 at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520270Drug excretion in human assessed as VP 44469 at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520261Drug excretion in human at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520250Terminal elimination half-life in human at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520262Renal clearance in human at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520255Drug excretion in human at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544458Ratio of EC50 for Human cytomegalovirus T2981 expressing UL27 kinase with W153R mutant gene to EC50 for Human cytomegalovirus T2211 expressing wild type UL27 gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520275AUC (0 to t) in human assessed as VP 44469 at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520283Toxicity in human assessed as dysgeusia at at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544463Ratio of EC50 for Human cytomegalovirus T3020 expressing UL27 kinase with E22stop gene to EC50 for Human cytomegalovirus T2211 expressing wild type UL27 gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520256Renal clearance in human at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544645Antiviral activity against Human cytomegalovirus clinical T2294 harboring UL97 T409M mutant gene with UL27 W153R mutant gene by SEAP yield reduction assay relative to wild type2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID544643Antiviral activity against 0.01 to 0.02 MOI of Human cytomegalovirus T2266 harboring UL97 deletion of 537 through the end mutant gene assessed as growth inhibition at day 6 by SEAP yield reduction assay relative to control2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID392517Antiviral activity against Human herpesvirus 6B2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID544447Antiviral activity against Human cytomegalovirus T2981 expressing UL27 kinase with W153R mutant gene by SEAP yield reduction assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID544637Ratio of EC50 for Human cytomegalovirus T3019 expressing UL27 kinase with 218delC mutant gene to EC50 for Human cytomegalovirus T2211 expressing wild type UL27 gene2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520277Volume of distribution with respect to oral bioavailability in human assessed as VP 44469 at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520249Cmax in human plasma at 400 mg, po after 24 hrs2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520245AUC (0 to t) in human at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID1450214Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for HSV-1 L2 infected in African green monkey Vero E6 cells2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID520274Terminal elimination half-life in human assessed as VP 44469 at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID520258Tmax in human plasma at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID544446Antiviral activity against Human cytomegalovirus T2890 expressing UL97 kinase with V353A mutant gene by SEAP yield reduction assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID544444Antiviral activity against Human cytomegalovirus T2211 expressing wild type UL27 kinase by SEAP yield reduction assay2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID544647Antiviral activity against Human cytomegalovirus clinical T2294 harboring UL97 T409 mutant gene with UL27 V353E mutant gene by SEAP yield reduction assay relative to wild type2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
AID520279Drug excretion in human assessed as VP 44469 at 400 mg, po administered with 400 mg ketoconazole after 7 days2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (115)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (1.74)18.2507
2000's40 (34.78)29.6817
2010's46 (40.00)24.3611
2020's27 (23.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.14 (24.57)
Research Supply Index4.93 (2.92)
Research Growth Index6.06 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (15.13%)5.53%
Reviews25 (21.01%)6.00%
Case Studies7 (5.88%)4.05%
Observational0 (0.00%)0.25%
Other69 (57.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]